Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.48 INR | -1.42% | -3.05% | +5.75% |
Valuation
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 9.229 | 16.04 | 46.4 | 115.3 | 129 | 488.8 |
Enterprise Value (EV) 1 | 7.395 | 14.97 | 46.18 | 113.3 | 124.9 | 328.2 |
P/E ratio | -2.39 x | -8.68 x | 150 x | 124 x | 89.4 x | -3.72 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 2.05 x | 3.33 x | - | 1.35 x | 3.27 x | - |
EV / Revenue | 1.65 x | 3.11 x | - | 1.32 x | 3.17 x | - |
EV / EBITDA | -1.92 x | -9.92 x | -13.8 x | 106 x | 91.1 x | -3.45 x |
EV / FCF | -853 x | -11.4 x | 1.33 x | 32 x | 37 x | -4.61 x |
FCF Yield | -0.12% | -8.79% | 75.5% | 3.13% | 2.71% | -21.7% |
Price to Book | 0.89 x | 1.87 x | 0.55 x | 1.35 x | 1.49 x | 2.09 x |
Nbr of stocks (in thousands) | 3,406 | 3,406 | 10,311 | 10,311 | 10,311 | 22,411 |
Reference price 2 | 2.710 | 4.710 | 4.500 | 11.18 | 12.51 | 21.81 |
Announcement Date | 13/08/18 | 31/08/19 | 21/08/20 | 30/08/21 | 23/07/22 | 31/08/23 |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 4.491 | 4.81 | - | 85.51 | 39.39 | - |
EBITDA 1 | -3.862 | -1.51 | -3.355 | 1.069 | 1.371 | -95.2 |
EBIT 1 | -3.872 | -1.524 | -3.743 | 0.6209 | 1.279 | -95.37 |
Operating Margin | -86.22% | -31.69% | - | 0.73% | 3.25% | - |
Earnings before Tax (EBT) 1 | -3.686 | -1.477 | -3.752 | 0.8843 | 1.403 | -99.08 |
Net income 1 | -3.857 | -1.847 | 0.3353 | 0.9331 | 1.451 | -75.56 |
Net margin | -85.88% | -38.4% | - | 1.09% | 3.68% | - |
EPS 2 | -1.133 | -0.5423 | 0.0300 | 0.0900 | 0.1400 | -5.860 |
Free Cash Flow 1 | -0.008668 | -1.316 | 34.85 | 3.542 | 3.381 | -71.24 |
FCF margin | -0.19% | -27.36% | - | 4.14% | 8.58% | - |
FCF Conversion (EBITDA) | - | - | - | 331.25% | 246.59% | - |
FCF Conversion (Net income) | - | - | 10,392.87% | 379.57% | 232.91% | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 13/08/18 | 31/08/19 | 21/08/20 | 30/08/21 | 23/07/22 | 31/08/23 |
Balance Sheet Analysis
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 1.83 | 1.07 | 0.22 | 2 | 4.07 | 161 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -0.01 | -1.32 | 34.9 | 3.54 | 3.38 | -71.2 |
ROE (net income / shareholders' equity) | -31.2% | -19.4% | 0.4% | 1.1% | 1.69% | -48.5% |
ROA (Net income/ Total Assets) | -14.6% | -8.15% | -2.73% | 0.44% | 0.79% | -33.4% |
Assets 1 | 26.42 | 22.66 | -12.27 | 211.3 | 183.7 | 226.3 |
Book Value Per Share 2 | 3.060 | 2.520 | 8.180 | 8.270 | 8.410 | 10.50 |
Cash Flow per Share 2 | 0.6900 | 0.3100 | 0.0200 | 0.1900 | 0.4000 | 5.940 |
Capex 1 | 0.03 | 0.02 | 0.42 | 0.02 | - | 16.7 |
Capex / Sales | 0.74% | 0.35% | - | 0.02% | - | - |
Announcement Date | 13/08/18 | 31/08/19 | 21/08/20 | 30/08/21 | 23/07/22 | 31/08/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+5.75% | 22.09M | |
+52.93% | 803B | |
+40.98% | 629B | |
-7.08% | 351B | |
+17.40% | 324B | |
+10.58% | 303B | |
+16.42% | 244B | |
+2.17% | 226B | |
+10.66% | 215B | |
+6.24% | 164B |
- Stock Market
- Equities
- 524572 Stock
- Financials Pharmaids Pharmaceuticals Limited